<DOC>
	<DOCNO>NCT01218438</DOCNO>
	<brief_summary>The purpose study develop 20 % subcutaneous ( SC ) immunoglobulin preparation treatment patient primary immunodeficiency disease ( PIDD ) .</brief_summary>
	<brief_title>Phase 2/3 Study IGSC , 20 % PIDD</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Main Documented diagnosis form primary humoral immunodeficiency involve defective antibody formation require gammaglobulin replacement define accord IUIS Scientific Committee , 2011 diagnostic criterion accord Conley et al . ( 1999 ) . The diagnosis must confirm Medical Director prior first treatment investigational product ( IP ) study . Participant 2 year old time screening , minimum body weight 13 kg . Written inform consent obtain either participant participant 's legally authorize representative prior studyrelated procedure study product administration Participant receive stable monthly equivalent dose IgG average minimum dose equivalent 300 mg/kg bodyweight ( BW ) /4 week maximum dose equivalent 1.0 gram/kg BW/4 week , minimum 12 week prior first treatment IP study . Serum trough level IgG &gt; 500 mg/dL screen Participant willing able comply requirement protocol Main Participant known history positive screen one following : hepatitis B surface antigen ( HBsAg ) , polymerase chain reaction ( PCR ) Hepatitis C virus ( HCV ) , PCR human immunodeficiency virus ( HIV ) Type 1/2 Abnormal laboratory value screen meet one follow criterion ( abnormal test may repeat determine persistent ) : Persistent alanine aminotransferase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 time upper limit normal test laboratory Persistent severe neutropenia ( define absolute neutrophil count [ ANC ] ≤500/mm^3 ) Creatinine clearance ( CLcr ) value &lt; 60 % normal age gender either measure , calculate accord CockcroftGault formula Malignancy ( adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix ) , unless diseasefree period prior screen exceeds 5 year Participant receive anticoagulation therapy ( low dose aspirin ≤325 mg/day permit ) history thrombotic episode ( include deep vein thrombosis , myocardial infarction , cerebrovascular accident , pulmonary embolism ) sickle cell disease crisis within 12 month prior screen history thrombophilia Abnormal protein loss ( protein lose enteropathy , nephrotic syndrome ) Anemia would preclude phlebotomy laboratory study accord standard practice site Acute serious bacterial infection within 3 month prior screen Ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow intravenous immunoglobulin , subcutaneous immunoglobulin , and/or Immune Serum Globulin ( ISG ) infusion Severe immunoglobulin A ( IgA ) deficiency ( le 0.07g/L ) know antiIgA antibody history hypersensitivity Participant continuous systemic antibacterial antibiotic dose sufficient treat prevent bacterial infection , , opinion investigator , stop duration study without put patient risk increase infection Participant active infection receive antibiotic therapy treatment infection time screen Bleeding disorder thrombocytopenia platelet count less 20,000/μL , , opinion investigator , would significant risk increase bleed bruise result subcutaneous therapy Total protein &gt; 9 g/dL myeloma macroglobulinemia ( IgM ) paraproteinemia Severe dermatitis would preclude adequate site safe product administration Women childbearing potential meeting one follow criterion : Participant present positive pregnancy test Participant breast feeding Participant intend begin nurse course study Participant agree employ adequate birthcontrol measure ( e.g . intrauterine device , diaphragm condom [ male partner ] spermicidal jelly foam , birth control pills/patches ) throughout course study Participation another clinical study exposure investigational product device within 30 day prior study enrollment ( exception : treatment previous Baxter immunoglobulin study ) Participant schedule participate another ( nonBaxter ) nonobservational ( interventional ) clinical study involve investigational product device course study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>